Globus Medical (NYSE:GMED) Releases FY 2025 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 3.750-3.85 for the period, compared to the consensus earnings per share estimate of 3.210. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $2.9 billion.

Analyst Upgrades and Downgrades

GMED has been the topic of a number of research analyst reports. Morgan Stanley decreased their target price on Globus Medical from $75.00 to $68.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 15th. Truist Financial upgraded shares of Globus Medical from a “hold” rating to a “buy” rating and raised their price objective for the company from $65.00 to $93.00 in a research report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a research report on Monday, July 21st. Wells Fargo & Company raised their price target on Globus Medical from $66.00 to $79.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Bank of America raised Globus Medical from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $65.00 to $91.00 in a research note on Friday. Nine equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $87.82.

Globus Medical Stock Performance

Shares of NYSE GMED traded up $22.28 during mid-day trading on Friday, hitting $83.99. The stock had a trading volume of 12,468,141 shares, compared to its average volume of 1,459,207. The business has a 50 day moving average price of $59.83 and a two-hundred day moving average price of $60.01. Globus Medical has a 1 year low of $51.79 and a 1 year high of $94.93. The firm has a market cap of $11.34 billion, a P/E ratio of 32.31, a price-to-earnings-growth ratio of 1.68 and a beta of 1.15.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, November 6th. The medical device company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.39. The business had revenue of $769.05 million for the quarter, compared to analyst estimates of $734.58 million. Globus Medical had a net margin of 13.58% and a return on equity of 10.65%. The company’s revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.83 EPS. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. Equities research analysts predict that Globus Medical will post 3.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Globus Medical news, Director Ann D. Rhoads sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $58.46, for a total transaction of $584,600.00. Following the completion of the transaction, the director owned 25,384 shares of the company’s stock, valued at $1,483,948.64. This represents a 28.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 18.51% of the stock is owned by insiders.

Institutional Investors Weigh In On Globus Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GMED. EverSource Wealth Advisors LLC raised its holdings in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of Globus Medical by 0.7% in the 2nd quarter. Corient Private Wealth LLC now owns 46,737 shares of the medical device company’s stock worth $2,756,000 after acquiring an additional 317 shares in the last quarter. Jones Financial Companies Lllp increased its stake in shares of Globus Medical by 237.3% in the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after acquiring an additional 598 shares in the last quarter. Headlands Technologies LLC increased its stake in shares of Globus Medical by 485.4% in the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after acquiring an additional 631 shares in the last quarter. Finally, Integrated Wealth Concepts LLC lifted its position in Globus Medical by 33.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after acquiring an additional 1,085 shares during the period. 95.16% of the stock is owned by hedge funds and other institutional investors.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.